13 August 2021 | Friday | News
Image Source : Public Domain
In a study presented at the Australasian Diabetes Congress today, researchers used PromarkerD, the world's first predictive diagnostic test for diabetic kidney disease or "DKD", to test blood samples from more than 2,000 type 2 diabetes patients who had taken part in a clinical trial of the drug.
The study found the average PromarkerD risk score of patients taking canagliflozin, an SGLT2-inhibitor diabetes drug, reduced significantly during the three-year trial.
PromarkerD is a simple biomarker-based blood test developed by Australian medical technology company Proteomics International Laboratories Ltd (ASX:PIQ). It is the only available test capable of reliably predicting future kidney function decline in patients with type 2 diabetes and no existing DKD[*]. The PromarkerD prognostic test can predict the onset of the asymptomatic disease up to four years in advance.
Canagliflozin is an approved diabetes therapy with additional renal and cardiovascular benefits. It is the first diabetes medicine approved by the US Food and Drug Administration (FDA) to treat DKD, and shown to slow the disease progression in patients with type 2 diabetes and DKD.
The study examined the association between canagliflozin and change in PromarkerD risk scores over a three-year period in type 2 diabetes patients in the completed CANagliflozin cardioVascular Assessment Study (CANVAS). The research retrospectively measured PromarkerD risk scores for developing DKD in blood samples from 2,008 patients taken at the start of the trial and again three years later. All patients had diabetes but no existing DKD, and were randomly allocated to take either canagliflozin or a placebo.
The study found the average PromarkerD risk score in patients taking canagliflozin dropped 1% during the trial, while the average risk score of patients taking a placebo rose 4%[†]. Importantly, the greatest reductions in risk score were seen in the patients classified by PromarkerD as being at high risk of developing DKD at the start of the trial - here the PromarkerD risk score of patients taking canagliflozin dropped 6%. Each of these results was statistically significant.
Proteomics International managing director Dr Richard Lipscombe said the research further validated the power of the PromarkerD test. "Our previously published clinical studies have shown the power of PromarkerD to predict the onset of diabetic kidney disease before clinical symptoms appear," he said.
"Now, for the first time, we are confirming that this SGLT2 inhibitor class of diabetes drug can improve people's renal risk profile. It means there is a potential treatment for type 2 diabetes patients identified by PromarkerD as being at high risk of diabetic kidney disease, giving them the chance to reduce their risk of developing symptoms in the future."
The study is being presented at the Australasian Diabetes Congress in Brisbane, from 11-13 August 2021.